Basal insulin - Answers from analogues?

Practical Diabetes International

Volumn 19, Issue 7, 2002, Pages 213-216

  Barnett, A H ^a  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Insulin analogues, basal insulin; Insulin glargine; Insulin treatment; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; ARGININE; ASPARAGINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GUM ARABIC; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; RECOMBINANT HUMAN INSULIN; SOMATOMEDIN C RECEPTOR; ZINC;

BLOOD FLOW; BOLUS INJECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CRYSTALLIZATION; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE CLASSIFICATION; DISEASE CONTROL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; INJECTION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISOELECTRIC POINT; LONG TERM CARE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PH; REVIEW;

EID: 0036710368     PISSN: 13578170     EISSN: None     Source Type: Journal    
DOI: 10.1002/pdi.383     Document Type: Review

References (30)

1. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-746.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes 1999; 48: 383-390.
5. Owens DR, Vora JP, Jones IR et al. Soluble and lente human insulin mixtures in normal man. Diabetes Care 1988; 7: 35-40.
6. Lepore M, Pampanelli S, Fanelli CG et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
7. Zinman B, Ross S, Campos R, Strack T. Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin Lispro multiple daily injection regimen. Diabetes Care 1999; 22: 603-608.
8. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-189.
9. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21: 1910-1914.
10. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999; 22 (Suppl. 2): B109-B113.
11. Jehle PM, Micheler C, Jehle DR, Breitig D, Boehm BO. Inadequate suspension of neutral protamine Hagedorn (NPH) insulin in pens. Lancet 1999; 354: 1604-1607.
12. Lindstrom T, Olsson PO, Arnqvist HJ. The use of human ultralente is limited by great intraindividual variability in overnight plasma insulin profiles. Scand J Clin Lab Invest 2000; 60: 341-347.
13. Simpson KL, Spencer CM. Insulin aspart. Drugs 1999; 57: 759-765.
14. Koivisto VA. The human insulin analogue insulin lispro. Ann Med 1998; 30: 260-266.
15. Bolli GB, Owens DR. Insulin glargine. Lancet 2000; 356: 443-445.
16. McKeague K, Goa KL. Insulin glargine. A review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus. Drugs 2001; 61: 1599-1624.
17. Pieber TP, Eugene-Jolcine I, Derobert E. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23: 157-162.
18. Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care 2000; 23: 1137-1142.
19. Ratner RE, Hersch IB, Neifing JL et al. Less hypoglycaemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 2001; 23: 639-643.
20. Raskin P, Klaff L, Bergenstal R et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23: 1666-1671.
21. Standl E. Results of an international, multicentred, randomised 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of type 1 diabetics [abstract]. Exp Clin Endocrinol Diabetes 2000; 108 (Suppl. 1): 159.
22. Hershon K, Blevins T, Donley D, Littlejohn C. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract]. Diabetes 2001; 50 (Suppl. 2): 116-117.
23. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia [abstract]. Diabetologia 1999; 42 (Suppl. 1): A235.
24. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000; 23: 1130-1136.
25. Rosenstock J, Schwartz SL, Clark CMJr et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001; 24: 631-636.
26. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycaemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract]. Diabetes 2001; 50 (Suppl. 2): 112-113.
27. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycaemic control in type 2 diabetes [abstract]. Diabetes 1998; 47 (Suppl. 1): A103.
28. Massi Benedetti M. Results of a 12-month study: insulin glargine (HOE 901) in combination with oral agents [abstract]. 35th Annual Meeting of the European Association for the Study of Diabetes (EASD), Brussels, 1999.
29. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
30. Thrailkill KM, Quattrin T, Baker L et al. Cotherapy with recombinant human insulin-like growth factor 1 and insulin improves glycaemic control in type 1 diabetes. RhIGF-I in IDDM Study Group. Diabetes Care 1999; 22: 585-592.